Pibrentasvir is an NS5A inhibitor antiviral agent.

[1] In the United States and Europe, it is approved for use with glecaprevir as the combination drug glecaprevir/pibrentasvir (trade name Mavyret in the US and Maviret in the EU) for the treatment of hepatitis C.[2][3] It is sold by Abbvie.

[citation needed] This antiinfective drug article is a stub.

You can help Wikipedia by expanding it.